Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer.

Adelaide newsreader Will McDonald has managed his aggressive stage 4 prostate cancer for six years now, although he knows the ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

Early cancer screening in Bengaluru helps detect breast, ovarian and prostate cancers sooner.

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...

aDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA bDepartment of Medicine Statistical Core, University of California, Los Angeles, Los Angeles, CA, USA ...

PROSTOX Standard targets CFRT (37–45 fractions) and MHFRT (20–28 fractions), expanding a regimen-specific platform aimed at predicting late GU toxicity after EBRT in localized prostate cancer.